Literature DB >> 33574333

M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Jamie-Lee S Mills1, Cesar M Jayashi Flores2, Manisha Pandey3, Michael F Good4, Simone Reynolds1, Christine Wun2, Ainslie Calcutt1, S Ben Baker2, Senthil Murugappan2, Alexandra C I Depelsenaire2, Jessica Dooley1, Paul V Fahey2, Angus H Forster5.   

Abstract

We evaluated vaccination against Streptococcus pyogenes with the candidate vaccine, J8-DT, delivered by a high-density microarray patch (HD-MAP). We showed that vaccination with J8-DT eluted from a coated HD-MAP (J8-DT/HD-MAP), induced similar total IgG responses to that generated by vaccination with J8-DT adjuvanted with Alum (J8-DT/Alum). We evaluated the effect of dose reduction and the number of vaccinations on the antibody response profile of vaccinated mice. A reduction in the number of vaccinations (from three to two) with J8-DT/HD-MAP induced comparable antibody responses to three vaccinations with intramuscular J8-DT/Alum. Vaccine-induced protection against an S. pyogenes skin challenge was assessed. J8-DT/HD-MAP vaccination led to a significant reduction in the number of S. pyogenes colony forming units in skin (92.9%) and blood (100%) compared to intramuscular vaccination with unadjuvanted J8-DT. The protection profile was comparable to that of intramuscular J8-DT/Alum. J8-DT/HD-MAP induced a shift in the antibody isotype profile, with a bias towards Th1-related isotypes, compared to J8-DT/Alum (Th2 bias). Based on the results of this study, the use of J8-DT/HD-MAP should be considered in future clinical development and control programs against S. pyogenes. Furthermore, the innate characteristics of the technology, such as vaccine stability and increased coverage, ease of use, reduction of sharp waste and the potential reduction of dose may be advantageous compared to current vaccination methods.

Year:  2020        PMID: 33574333     DOI: 10.1038/s41541-020-00222-2

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  47 in total

1.  Progress toward a global group a streptococcal vaccine.

Authors:  Andrew C Steer; James B Dale; Jonathan R Carapetis
Journal:  Pediatr Infect Dis J       Date:  2013-02       Impact factor: 2.129

Review 2.  The inequitable burden of group A streptococcal diseases in Indigenous Australians.

Authors:  Philippa J May; Asha C Bowen; Jonathan R Carapetis
Journal:  Med J Aust       Date:  2016-09-05       Impact factor: 7.738

Review 3.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

Review 4.  Tissue tropisms in group A Streptococcus: what virulence factors distinguish pharyngitis from impetigo strains?

Authors:  Debra E Bessen
Journal:  Curr Opin Infect Dis       Date:  2016-06       Impact factor: 4.915

Review 5.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

6.  High burden of invasive group A streptococcal disease in the Northern Territory of Australia.

Authors:  R Boyd; M Patel; B J Currie; D C Holt; T Harris; V Krause
Journal:  Epidemiol Infect       Date:  2015-09-14       Impact factor: 2.451

Review 7.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

8.  An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline.

Authors:  Jonathan R Carapetis; Alex Brown; Nigel J Wilson; Keith N Edwards
Journal:  Med J Aust       Date:  2007-06-04       Impact factor: 7.738

9.  Identification and Characterization of Fluoroquinolone Non-susceptible Streptococcus pyogenes Clones Harboring Tetracycline and Macrolide Resistance in Shanghai, China.

Authors:  Yinfang Shen; Jiehao Cai; Mark R Davies; Chi Zhang; Kun Gao; Dan Qiao; Haoqin Jiang; Weilei Yao; Yuefang Li; Mei Zeng; Mingliang Chen
Journal:  Front Microbiol       Date:  2018-03-23       Impact factor: 5.640

10.  Whole genome sequencing reveals extensive community-level transmission of group A Streptococcus in remote communities.

Authors:  A C Bowen; T Harris; D C Holt; P M Giffard; J R Carapetis; P T Campbell; J McVERNON; S Y C Tong
Journal:  Epidemiol Infect       Date:  2016-02-01       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.